Post COVID-19 ConditionPhase 3PYCNOVIDNCT05890534
Pycnogenol® in Post-COVID-19 Condition
A Phase 3 study testing Pycnogenol® in people with Post COVID-19 Condition and Long COVID, run by University of Zurich at 1 site in Switzerland.
Trial summary
To determine the effect of Pycnogenol® versus placebo on patient-reported health status in people with post COVID-19 condition. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Post COVID-19 Condition, Long COVID
- What is being tested?
- Pycnogenol®
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 153 participants
- Where
- 1 siteSwitzerland
- Study dates
- 7 Jun 2023to 31 Jan 2025
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- SARS-CoV-2 infection confirmed by positive PCR or rapid antigen test for professional use or written medical report
- Post-COVID condition (WHO definition), i.e., ≥ 3 months after SARS-CoV2 infection and ongoing or recurring symptoms for at least 2 months that cannot be explained by alternative diagnosis
- Symptoms include fatigue and / or cognitive impairment ("brain fog") and / or dyspnea and / or post-exertional malaise
- Willing to participate and having signed informed consent
- Sufficient language and cognitive skills
- Ability to participate in study visits
- No foreseeable change in medication
Who cannot join
- Severe comorbidities such as liver or renal failure, advanced COPD or pulmonary fibrosis requiring > 5L oxygen/min at rest, active malignancy, advanced heart failure, cardio-vascular events within the previous 24 weeks (such as unstable coronary artery disease, coronary revascularization, myocardial infarction, stroke, transient ischemic attack, critical limb ischemia, pulmonary embolism, deep vein thrombosis), uncontrolled severe hypertension, uncontrolled diabetes uncontrolled autoimmune or inflammatory disease (the responsible study physician will decide each case on an individual basis)
- Acute respiratory or other infections (postpone baseline visit until resolved)
- Clinical diagnosis of a psychiatric disease (e.g., depression, anxiety disorder, schizophrenia) that is untreated and/or unstable (the responsible study physician will decide each case on an individual basis)
- COVID-19 vaccination less than 4 weeks prior to the baseline visit (i.e., first or second dose of a two-dose vaccination regimen, first dose of a single dose vaccination regimen, booster) or during study participation (booster shot will be offered at screening visit, wait time until baseline visit 4 weeks)
- Known intolerance of the study drug
- Regular intake of Pycnogenol®
- Pregnancy or lactating. For women and transgender individuals of childbearing age, who can anamnestically not exclude a pregnancy, are offered a pregnancy test during the study visits.
- Being enrolled in another interventional study that may interfere with the current study (the responsible study physician will decide each case on an individual basis)
Trial locations and contacts
1 site in 1 country.
Switzerland1 site
University of Zurich, Epidemiology, Biostatistics and Prevention Institute, Department of Public & Global Health
Zurich, 8001
About this study
Official title: Pycnogenol® in People With Post-COVID-19 Condition: a Quadruple-blind, Randomized, Placebo-controlled Trial
To determine the effect of Pycnogenol® versus placebo on patient-reported health status in people with post COVID-19 condition.
Read the detailed description
The primary aim of this 12-week quadruple blind, single-center randomized controlled trial is to determine the effect of Pycnogenol® (200mg daily) versus placebo on patient-reported health status (EQ-Visual Analogue Scale) in people with post COVID-19 condition. Secondary outcomes include symptoms, fatigue, cognitive function, health-related quality of life, functional exercise capacity and blood biomarkers of inflammation, endothelial function and oxidative stress.
Pycnogenol® is a licensed pine tree bark extract (Pinus pinaster ssp. atlantica) and primarly used for the treatment of venous disorders. Various studies reported beneficial effects in other conditions such as diabetes, metabolic syndrome and cardiovascular disorders. Pycnogenol® exerts antioxidative, anti-inflammatory and antiproliferative effects and has been shown to improve vascular endothelial function. Pycnogenol® may have potential to improve the health status of people suffering from post COVID-19 condition.
This trial lasts for 12 weeks. Participants are invited to visit the study center four times: screening visit, baseline visit, follow-up 1 visit (6 weeks after baseline visit), follow-up 2 visit (12 weeks after baseline visit).
In a substudy using baseline data, the investigators plan to study associations between objectively measured physical activity, severity of post COVID-19 condition, symptom burden and severity (e.g., fatigue, dyspnoea), functional exercise capacity, and health-related quality of life.
- Conditions
- Post COVID-19 Condition, Long COVID
- Being tested
- Pycnogenol®, Placebo
- Keywords
- COVID-19, post COVID symptoms, Pycnogenol®
- Medical subject headings
- Post-Acute COVID-19 Syndrome, COVID-19
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Pycnogenol®Drug
Single center, quadruple blind randomized controlled trial comparing Pycnogenol® versus Placebo.
PlaceboDrug
Single center, quadruple blind randomized controlled trial comparing Pycnogenol® versus Placebo.
| Study group | Role | What they receive |
|---|---|---|
| Pycnogenol® | Experimental | People with post COVID-19 condition randomly allocated to the Pycnogenol® arm will take 4 capsules of Pycnogenol® per day (4x50mg capsules, 200mg total) over a period of 12 weeks. Receives: Drug: Pycnogenol® |
| Placebo | Placebo comparator | People with post COVID-19 condition randomly allocated to the Placebo arm will take 4 capsules of Placebo per day (4x50mg capsules, 200mg total) over a period of 12 weeks. Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Health status (EQ-VAS)
EQ-Visual Analogue Scale (EQ-VAS also known as "Feeling thermometer") assessed daily over 7 consecutive days prior to the baseline and at the end of the follow-up 2 visit (i.e., study end after 12 weeks). The scale ranges from 0-100 with 0 representing worst health status and 100 representing best health status.
Measured: Change from baseline to 12 weeks
Secondary outcomes (24)
Post COVID-19 symptoms
Symptoms (present/not present) and symptom severity (5- point Likert scale: 1=not bad at all, 2=mild, 3=moderate, 4=severe, 5=very severe) will be assessed using a self-administered online questionnaire. Symptoms will also be recorded in a paper diary and completed on a weekly basis.
Measured: Change from baseline to 12 weeks
Fatigue
Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-F). 13-item questionnaire with a 7-day recall period assessed at baseline and after 12 weeks. The level of fatigue is measured on a 5-point Likert scale (4 = not at all fatigued to 0 = very much fatigued). Individual item scores are summed, with lower scores indicating more severe fatigue.
Measured: Change from baseline to 12 weeks
Dyspnea
Symptom domain of the Chronic Respiratory Questionnaire (CRQ) assessed at baseline and after 12 weeks. The questionnaire contains 5 questions; 7-point Likert-type scale ranging from 1 (most severe dyspnea) to 7 (no dyspnea).
Measured: Change from baseline to 12 weeks
Cognitive function
Montreal Cognitive Assessment (MoCA) assessed at baseline and after 12 weeks. The cut-off score < 26 for cognitive impairment will be used in this study.
Measured: Change from baseline to 12 weeks
Anxiety and depression
Hospital, Anxiety and Depression Scale (HADS) assessed at baseline and after 12 weeks. Symptoms of depression and anxiety (14 questions, 4-point Likert-type scale).
Measured: Change from baseline to 12 weeks
Health-related quality of life (EQ-5D-5L)
The EQ-5D-5L assesses the 5 dimensions mobility, self-care, usual activities, pain/discomfort, anxiety/depression. The EQ-5D-5L scores each dimension on five levels of severity ranging from 1 = "no problems" to 5 = "extreme problems. The instrument will be used at baseline and after 12 weeks.
Measured: Change from baseline to 12 weeks
Functional exercise capacity
A 30 second Sit-to-Stand (STS) will be performed at baseline and after 12 weeks. The number of repetitions that the participant completes the full sit-to-stand movement on a chair during 30 seconds. A familiarisation test will be done at the screening visit to rule out potential learning effects.
Measured: Change from baseline to 12 weeks
Physical activity
Physical activity measured with an accelerometer (ActiGraph wGT3X-BT, Pensacola, FL, USA), which is worn at the right hip over 8 consecutive days prior to the baseline and 12 week study visit. Number of daily steps and time spent in different intensity domains (min per day) will be analysed.
Measured: Change from baseline to 12 weeks
Soluble Thrombomodulin (sTM)
Blood biomarker of endothelial health measured with Enzyme-linked Immunosorbent Assay (ELISA) or Luminex (bead-based immunoassay) at baseline and after 12 weeks.
Measured: Change from baseline to 12 weeks
von Willebrand Factor antigen (VWF:Ag)
Blood biomarker of endothelial health measured with Enzyme-linked Immunosorbent Assay (ELISA) or Luminex (bead-based immunoassay) at baseline and after 12 weeks.
Measured: Change from baseline to 12 weeks
Syndecan-1
Blood biomarker of endothelial health measured with Enzyme-linked Immunosorbent Assay (ELISA) or Luminex (bead-based immunoassay) at baseline and after 12 weeks.
Measured: Change from baseline to 12 weeks
Circulating Cascular Cell Adhesion Molecule-1 (sVCAM 1)
Blood biomarker of endothelial health measured with Enzyme-linked Immunosorbent Assay (ELISA) or Luminex (bead-based immunoassay) at baseline and after 12 weeks.
Measured: Change from baseline to 12 weeks
C-reative protein (CRP)
Marker of inflammation (serum) measured at baseline and after 12 weeks by a certified laboratory (Analytica, Zurich, Switzerland).
Measured: Change from baseline to 12 weeks
Interleukine 6 (IL 6)
Marker of inflammation measured with Enzyme-linked Immunosorbent Assay (ELISA) or Luminex (bead-based immunoassay) at baseline and after 12 weeks.
Measured: Change from baseline to 12 weeks
sCD40L
Marker of coagulation and platelet function measured with Enzyme-linked Immunosorbent Assay (ELISA) or Luminex (bead-based immunoassay) at baseline and after 12 weeks.
Measured: Change from baseline to 12 weeks
sP selectin
Adhesion molecule measured with Enzyme-linked Immunosorbent Assay (ELISA) or Luminex (bead-based immunoassay) at baseline and after 12 weeks.
Measured: Change from baseline to 12 weeks
D-Dimer
Marker of coagulation and platelet function measured in citrate blood at baseline and after 12 weeks by certified laboratory (Analytica, Zurich, Switzerland).
Measured: Change from baseline to 12 weeks
Activated partial thromboplastin time (aPTT)
Marker of coagulation and platelet function measured in citrate blood at baseline and after 12 weeks by certified laboratory (Analytica, Zurich, Switzerland).
Measured: Change from baseline to 12 weeks
International normalized ratio (INR) blood test
Marker of coagulation and platelet function measured in citrate blood at baseline and after 12 weeks by certified laboratory (Analytica, Zurich, Switzerland).
Measured: Change from baseline to 12 weeks
Total antioxidant capacity (TAC)
Marker of oxidative stress measured in blood plasma at baseline and after 12 weeks. TAC will be measured using the well-established Ferric Reduction Capability of Plasma (FRAP) method using a commercially available kit.
Measured: Change from baseline to 12 weeks
Aspartate aminotransferase (ASAT)
Marker of liver function measured in blood serum at baseline and after 12 weeks by a certified laboratory (Analytica, Zurich, Switzerland).
Measured: Change from baseline to 12 weeks
Alanine aminotransferase (ALAT)
Livery enzyme measured in blood serum at baseline and after 12 weeks by a certified laboratory (Analytica, Zurich, Switzerland).
Measured: Change from baseline to 12 weeks
Gamma glutamyltransferase (γ-GT)
Livery enzyme measured in blood serum at baseline and after 12 weeks by a certified laboratory (Analytica, Zurich, Switzerland).
Measured: Change from baseline to 12 weeks
Creatinine
Creatinine including clearance measured in blood serum at baseline and after 12 weeks by a certified laboratory (Analytica, Zurich, Switzerland).
Measured: Change from baseline to 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Jun 2023
- Study start7 Jun 2023
- Primary completion5 Nov 2024
- Study completion31 Jan 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Post COVID-19 ConditionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 153 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Zurich
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Jahn S Fehr, Prof., MD, Study director, University of Zurich, EBPI, Department of Public & Global HealthAlexia Anagnostopoulos, MD, Principal investigator, University of Zurich, EBPI, Department of Public & Global Health
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05890534
- Sponsor's protocol ID
- 2022-01967
- Acronym
- PYCNOVID
- Status last verified
- Apr 2026
- First submitted
- 5 Jun 2023
- Last updated
- 29 Apr 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Kopp J, Ballouz T, Menges D, Frei A, Braun J, Kuenzi L, Puhan MA, Fehr JS, Radtke T. Within-person variability and the minimal important difference of the EQ-VAS in adults with post-COVID-19 condition: a secondary analysis of data from a single-centre randomised controlled trial. BMJ Open. 2026 Sep 25;16(9):e121051. doi: 10.1136/bmjopen-2026-121051.
PubMed 42790915Braun J, Kopp J, Kunzi L, Puhan MA, Fehr JS, Radtke T. Measurement properties of the 30-second sit-to-stand test in post COVID-19 condition: Results from the PYCNOVID randomised controlled trial. PLoS One. 2026 May 12;21(5):e0348275. doi: 10.1371/journal.pone.0348275. eCollection 2026.
PubMed 42118816Radtke T, Kunzi L, Kopp J, Rasi M, Braun J, Zens KD, Winter B, Anagnostopoulos A, Puhan MA, Fehr JS. Effects of Pycnogenol(R) in people with post-COVID-19 condition (PYCNOVID): study protocol for a single-center, placebo controlled, quadruple-blind, randomized trial. Trials. 2024 Jun 15;25(1):385. doi: 10.1186/s13063-024-08187-6.
PubMed 38879571
Study at a glance
From the registry record, last updated by the sponsor on 29 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Pycnogenol® in People With Post-COVID-19 Condition: a Quadruple-blind, Randomized, Placebo-controlled Trial
- ClinicalTrials.gov ID
- NCT05890534
- Acronym / sponsor ID
- PYCNOVID / 2022-01967
- Conditions
- Post COVID-19 Condition, Long COVID
- Keywords
- COVID-19, post COVID symptoms, Pycnogenol®
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 153 participants (actual)
- Lead sponsor
- University of ZurichUniversity, hospital or other
- Study start
- 7 Jun 2023 (actual)
- Primary completion
- 5 Nov 2024 (actual)
- Study completion
- 31 Jan 2025 (actual)
- First posted
- 6 Jun 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To determine the effect of Pycnogenol® versus placebo on patient-reported health status in people with post COVID-19 condition.
Detailed description
The primary aim of this 12-week quadruple blind, single-center randomized controlled trial is to determine the effect of Pycnogenol® (200mg daily) versus placebo on patient-reported health status (EQ-Visual Analogue Scale) in people with post COVID-19 condition. Secondary outcomes include symptoms, fatigue, cognitive function, health-related quality of life, functional exercise capacity and blood biomarkers of inflammation, endothelial function and oxidative stress.
Pycnogenol® is a licensed pine tree bark extract (Pinus pinaster ssp. atlantica) and primarly used for the treatment of venous disorders. Various studies reported beneficial effects in other conditions such as diabetes, metabolic syndrome and cardiovascular disorders. Pycnogenol® exerts antioxidative, anti-inflammatory and antiproliferative effects and has been shown to improve vascular endothelial function. Pycnogenol® may have potential to improve the health status of people suffering from post COVID-19 condition.
This trial lasts for 12 weeks. Participants are invited to visit the study center four times: screening visit, baseline visit, follow-up 1 visit (6 weeks after baseline visit), follow-up 2 visit (12 weeks after baseline visit).
In a substudy using baseline data, the investigators plan to study associations between objectively measured physical activity, severity of post COVID-19 condition, symptom burden and severity (e.g., fatigue, dyspnoea), functional exercise capacity, and health-related quality of life.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Pycnogenol® | Experimental | Drug: Pycnogenol®People with post COVID-19 condition randomly allocated to the Pycnogenol® arm will take 4 capsules of Pycnogenol® per day (4x50mg capsules, 200mg total) over a period of 12 weeks. |
| Placebo | Placebo comparator | Drug: PlaceboPeople with post COVID-19 condition randomly allocated to the Placebo arm will take 4 capsules of Placebo per day (4x50mg capsules, 200mg total) over a period of 12 weeks. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- SARS-CoV-2 infection confirmed by positive PCR or rapid antigen test for professional use or written medical report
- Post-COVID condition (WHO definition), i.e., ≥ 3 months after SARS-CoV2 infection and ongoing or recurring symptoms for at least 2 months that cannot be explained by alternative diagnosis
- Symptoms include fatigue and / or cognitive impairment ("brain fog") and / or dyspnea and / or post-exertional malaise
- Willing to participate and having signed informed consent
- Sufficient language and cognitive skills
Key exclusion criteria (8 listed)
- Severe comorbidities such as liver or renal failure, advanced COPD or pulmonary fibrosis requiring > 5L oxygen/min at rest, active malignancy, advanced heart failure, cardio-vascular events within the previous 24 weeks (such as unstable coronary artery disease, coronary revascularization, myocardial infarction, stroke, transient ischemic attack, critical limb ischemia, pulmonary embolism, deep vein thrombosis), uncontrolled severe hypertension, uncontrolled diabetes uncontrolled autoimmune or inflammatory disease (the responsible study physician will decide each case on an individual basis)
- Acute respiratory or other infections (postpone baseline visit until resolved)
- Clinical diagnosis of a psychiatric disease (e.g., depression, anxiety disorder, schizophrenia) that is untreated and/or unstable (the responsible study physician will decide each case on an individual basis)
- COVID-19 vaccination less than 4 weeks prior to the baseline visit (i.e., first or second dose of a two-dose vaccination regimen, first dose of a single dose vaccination regimen, booster) or during study participation (booster shot will be offered at screening visit, wait time until baseline visit 4 weeks)
- Known intolerance of the study drug
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Pycnogenol®Single center, quadruple blind randomized controlled trial comparing Pycnogenol® versus Placebo. | Drug | Pycnogenol® |
| PlaceboSingle center, quadruple blind randomized controlled trial comparing Pycnogenol® versus Placebo. | Drug | Placebo |
Primary outcome
Health status (EQ-VAS)
Time frame: Change from baseline to 12 weeks
EQ-Visual Analogue Scale (EQ-VAS also known as "Feeling thermometer") assessed daily over 7 consecutive days prior to the baseline and at the end of the follow-up 2 visit (i.e., study end after 12 weeks). The scale ranges from 0-100 with 0 representing worst health status and 100 representing best health status.
24 secondary outcomes
Post COVID-19 symptoms
Time frame: Change from baseline to 12 weeks
Fatigue
Time frame: Change from baseline to 12 weeks
Dyspnea
Time frame: Change from baseline to 12 weeks
Cognitive function
Time frame: Change from baseline to 12 weeks
Anxiety and depression
Time frame: Change from baseline to 12 weeks
Health-related quality of life (EQ-5D-5L)
Time frame: Change from baseline to 12 weeks
Functional exercise capacity
Time frame: Change from baseline to 12 weeks
Physical activity
Time frame: Change from baseline to 12 weeks
Soluble Thrombomodulin (sTM)
Time frame: Change from baseline to 12 weeks
von Willebrand Factor antigen (VWF:Ag)
Time frame: Change from baseline to 12 weeks
Syndecan-1
Time frame: Change from baseline to 12 weeks
Circulating Cascular Cell Adhesion Molecule-1 (sVCAM 1)
Time frame: Change from baseline to 12 weeks
C-reative protein (CRP)
Time frame: Change from baseline to 12 weeks
Interleukine 6 (IL 6)
Time frame: Change from baseline to 12 weeks
sCD40L
Time frame: Change from baseline to 12 weeks
sP selectin
Time frame: Change from baseline to 12 weeks
D-Dimer
Time frame: Change from baseline to 12 weeks
Activated partial thromboplastin time (aPTT)
Time frame: Change from baseline to 12 weeks
International normalized ratio (INR) blood test
Time frame: Change from baseline to 12 weeks
Total antioxidant capacity (TAC)
Time frame: Change from baseline to 12 weeks
Aspartate aminotransferase (ASAT)
Time frame: Change from baseline to 12 weeks
Alanine aminotransferase (ALAT)
Time frame: Change from baseline to 12 weeks
Gamma glutamyltransferase (γ-GT)
Time frame: Change from baseline to 12 weeks
Creatinine
Time frame: Change from baseline to 12 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Apr 2026.
- Derived from this study: PubMed 42790915Kopp J, Ballouz T, Menges D, Frei A, Braun J, Kuenzi L, Puhan MA, Fehr JS, Radtke T. Within-person variability and the minimal important difference of the EQ-VAS in adults with post-COVID-19 condition: a secondary analysis of data from a single-centre randomised controlled trial. BMJ Open. 2026 Sep 25;16(9):e121051. doi: 10.1136/bmjopen-2026-121051.
- Derived from this study: PubMed 42118816Braun J, Kopp J, Kunzi L, Puhan MA, Fehr JS, Radtke T. Measurement properties of the 30-second sit-to-stand test in post COVID-19 condition: Results from the PYCNOVID randomised controlled trial. PLoS One. 2026 May 12;21(5):e0348275. doi: 10.1371/journal.pone.0348275. eCollection 2026.
- Derived from this study: PubMed 38879571Radtke T, Kunzi L, Kopp J, Rasi M, Braun J, Zens KD, Winter B, Anagnostopoulos A, Puhan MA, Fehr JS. Effects of Pycnogenol(R) in people with post-COVID-19 condition (PYCNOVID): study protocol for a single-center, placebo controlled, quadruple-blind, randomized trial. Trials. 2024 Jun 15;25(1):385. doi: 10.1186/s13063-024-08187-6.
- Individual participant dataSharing planned: No
Related trials for Post COVID-19 Condition
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Active, not recruiting
Long COVID Brain Fog: Cognitive Rehabilitation Trial
Long COVID, Brain Fog
Active, not recruitingObservational study
Korean Post Marketing Surveillance for Comirnaty Injection (Bretovameran)
COVID-19 Vaccination
Recruiting
ME/CFS Brain Fog: Cognitive Rehabilitation Trial
ME/CFS, ME/CFS Following EBV-associated Infectious Mononucleosis
RecruitingPhase 2
SARS-CoV-2 and Herpesvirus Inhibition for Ending Long COVID Dysfunction
Post-acute Sequelae of COVID-19, Long COVID
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jahn S Fehr, Prof., MD study director
University of Zurich, EBPI, Department of Public & Global Health
Alexia Anagnostopoulos, MD principal investigator
University of Zurich, EBPI, Department of Public & Global Health
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Pycnogenol® in people with Post COVID-19 Condition and Long COVID, run by University of Zurich at 1 site in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 29 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Health status (EQ-VAS) (time frame: Change from baseline to 12 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05890534, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Apr 2026.